MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Monopar Therapeutics
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$71.47+2.20 (+3.18%)
Close on Oct 19, 2026
- Market cap
- $610.53M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$8.66 (−10.81%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Monopar Therapeutics reported revenue of $0 for fiscal 2025.
Revenue
$0
FY2025
Operating income
-$22.12M
TTM Q2 2026
EPS, diluted
-$2.17
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $610.53M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.67
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$17.84M
- EPS, diluted
- -$2.17
- Book value per share
- $15.32
- Diluted shares
- 9M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$22.12M
Net income
-$17.84M
EPS, diluted
-$2.17
Reported periodTrailing twelve months